Refreshing results…
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
UploadPlasma phosphorylated tau 217 in preclinical Alzheimer’s disease
Download from doi.orgBlood‐based biomarkers for Alzheimer's disease
Download from doi.orgPlasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
UploadSoluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Download from doi.orgEarly stages of tau pathology and its associations with functional connectivity, atrophy and memory
Download from onlinelibrary.wiley.comUntangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
UploadThe accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
Download from academic.oup.comIncreasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Download from www.nature.comLongitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
Download from academic.oup.comCDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
Download from doi.orgCerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
Download from www.nature.comMissing publications? Search for publications with a matching author name.